Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | ABL1 | P00519 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | IDE | P14735 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | HLCS | P50747 | 6/20 | 0.63 |
| ▸ | CA12 | O43570 | 7/20 | 0.52 |
| ▸ | CA1 | P00915 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.52 |
| ▸ | CA9 | Q16790 | 7/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13958687 | 0.88 | TDP1 (0.91) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL4314463 | 0.88 | TDP1 (0.91) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL16900247 | 0.88 | TDP1 (0.91) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL16379530 | 0.88 | TDP1 (0.91) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL9557437 | 0.86 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL3262330 | 0.86 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL8081758 | 0.85 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8164531 | 0.84 | TDP1 (0.75) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23055065 | 0.84 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL20547409 | 0.84 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 762 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4416303-A1 | A MICROSPHERE COMPRISING A FIRST MATERIAL AND A SECOND MATERIAL | Blink AG (DE) | 2024-08-21 | — | — | EP | claimed |
| CN-118510909-A | Microsphere comprising a first material and a second material | 布林克公司 | 2024-08-16 | — | — | CN | claimed |
| US-20240084354-A1 | MEANS AND METHODS FOR REGULATING INTRACELLULAR TRAFFICKING OF SECRETORY OR CELL MEMBRANE-ANCHORED PROTEINS OF INTEREST | HONING BIOSCIENCES (FR) | 2024-03-14 | — | — | US | claimed |
| EP-4244240-A1 | MEANS AND METHODS FOR REGULATING INTRACELLULAR TRAFFICKING OF SECRETORY OR CELL MEMBRANE-ANCHORED PROTEINS OF INTEREST | Honing Biosciences (FR) | 2023-09-20 | — | — | EP | claimed |
| WO-2023154852-A1 | ANTIBODY BARCODED BEADS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-08-17 | — | — | WO | claimed |
| WO-2023079140-A1 | A MICROSPHERE COMPRISING A FIRST MATERIAL AND A SECOND MATERIAL | BLINK AG (DE) | 2023-05-11 | — | — | WO | claimed |
| EP-4177352-A1 | A MICROSPHERE COMPRISING A FIRST MATERIAL AND A SECOND MATERIAL | Blink AG (DE) | 2023-05-10 | — | — | EP | claimed |
| US-20230126528-A1 | A LIBRARY OF PREFABRICATED MICROPARTICLES AND PRECURSORS THEREOF | BLINK AG (DE) | 2023-04-27 | — | — | US | claimed |
| CN-110291095-B | Adenosine analogues and their use in regulating circadian clock | 北京生命科学研究所 | 2023-04-18 | — | — | CN | claimed |
| EP-4078180-A1 | A LIBRARY OF PREFABRICATED MICROPARTICLES AND PRECURSORS THEREOF | Blink AG (DE) | 2022-10-26 | — | — | EP | claimed |
| US-20010023288-A1 | Trifunctional reagent for conjugation to a biomolecule | GLYCOREX TRANSPLANTATION AB (SE) | 2001-09-20 | — | — | US | claimed |
| EP-1095274-A1 | TRIFUNCTIONAL REAGENT FOR CONJUGATION TO A BIOMOLECULE | Department of Radiation Oncology, University of Washington (US) | 2001-05-02 | — | — | EP | claimed |
| WO-2000002051-A1 | TRIFUNCTIONAL REAGENT FOR CONJUGATION TO A BIOMOLECULE | DEPT. OF RADIATION ONCOLOGY, UNIVERSITY OF WASHINGTON (US) | 2000-01-13 | — | — | WO | claimed |
| WO-2000002050-A1 | TRIFUNCTIONAL REAGENT FOR CONJUGATION TO A BIOMOLECULE | DEPARTMENT OF RADIATION ONCOLOGY, UNIVERSITY OF WASHINGTON (US) | 2000-01-13 | — | — | WO | claimed |
| EP-0717848-A1 | BIOTIN-ANALOG CONJUGATED ANTIBODIES FOR POSITIVE CELL SELECTION AND RELEASE | BAXTER INTERNATIONAL INC. (US) | 1996-06-26 | — | — | EP | claimed |
| WO-1995007466-A2 | BIOTIN-ANALOG CONJUGATED ANTIBODIES FOR POSITIVE CELL SELECTION AND RELEASE | BAXTER INTERNATIONAL INC. (US) | 1995-03-16 | — | — | WO | claimed |
| US-5108921-A | Contacting living cell membrane with complex of biotin and derivatives and biologically functional molecules; modifying cell function | PURDUE RESEARCH FOUNDATION (US) | 1992-04-28 | — | — | US | claimed |
| EP-0088542-B1 | SKIN TREATMENT COMPOSITION | UNILEVER N.V. (NL) | 1988-05-11 | — | — | EP | claimed |
| US-4529587-A | Using biotin antagonist | LEVER BROTHERS COMPANY (US) | 1985-07-16 | — | — | US | claimed |
| EP-0088542-A2 | Skin treatment composition | UNILEVER N.V. (NL) | 1983-09-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023288-A1 | Trifunctional reagent for conjugation to a biomolecule | CD40, UACA, CD47 | TDP1 3897/4885MEN1 2988/4885ABL1 483/4885 |
| US-20240084354-A1 | MEANS AND METHODS FOR REGULATING INTRACELLULAR TRAFFICKING OF SECRETORY OR CELL MEMBRANE-ANCHORED PROTEINS OF INTEREST | PHAX, SCAMP2, YIPF5 | TDP1 2678/4885MEN1 2782/4885ABL1 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.